Evolution Biotechnologies announces opening of new corporate facility at Colworth Science Park

Evolution Biotehnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the opening of its office at Colworth Science Park in Bedfordshire. This is intended to keystone the development of the company’s laboratory and other facilities at this location over the next year. The office is managed by Ms. Hayley Styche, who has joined the company in an administrative role.
Dr. David Harper, Chief Officer of Evolution, said “This is an important step for the company, and Colworth is the ideal location for our business to develop and grow. Ms. Styche has extensive experience in the sector and is a valuable addition to the company.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.

About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email: enquiries@evolutionbiotech.com

Website: www.evolutionbiotech.com

Completion of initial funding round and appointment of Chief Operating Officer

Evolution Biotechnologies announces completion of initial funding round and appointment of Chief Operating Officer

Evolution Biotehnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the closure of its first funding round, having raised the full sum sought at this time. The investment will support the establishment of the company’s development streams and central corporate facility ahead of further funding rounds. Further announcements on staff appointments and activities are planned for the near future.
The company also announced the appointment of Mr. Aaron Gunn to the board and to the post of Chief Operating Officer of the company. Dr. David Harper, Chief Officer of Evolution, said “I am delighted to welcome Aaron to the board and look forward to working with him as COO. His experience of building businesses in the very competitive environment of the US will bring much added value to the company, both immediately and in the future”.
About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.
About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.
Forward-looking statements
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email: enquiries@evolutionbiotech.com

Website: www.evolutionbiotech.com

Dr. David Harper interviewed for the financial website SeekingAlpha

Evolution Biotechnologies founder Dr. David Harper interviewed for the financial website SeekingAlpha

Dr. David Harper, the founder of Evolution Biotechnologies(www.evolutionbiotech.com), has been interviewed for the US financial website SeekingAlpha (seekingalpha.com). The interview covered both Dr. Harper’s previous work on bacteriophage therapy and the new technologies being developed by Evolution Biotechnologies.
The SeekingAlpha website states: “Today I had the privilege of interviewing Dr. David Harper, who just recently departed as Chief Science Officer of AmpliPhi Biosciences (OTCQB:APHB). Founder of the infectious disease pioneer Biocontrol, which conducted the first human clinical trial of a bacteriophage, Dr. Harper is a member of the Alternatives to Antibiotics panel, a collaboration between the Wellcome Trust and the UK Department of Health. We discuss the growing threat to our healthcare system posed by drug-resistant bacteria, some of the alternatives to conventional antibiotics the panel is looking at, and some of the companies in the space he believes investors should keep their eyes on. In the interview he provides an insider’s view on the work that has been done to date with bacteriophages, discusses their potential use as a biological control, and gives us the lowdown on his new venture, Evolution Biotechnologies.
About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.
About biological control
 
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.
Forward-looking statements
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.
Media contacts

Evolution Biotechnologies announces filing for House Dust Mite

Evolution Biotechnologies announces filing of its first patent application relating to the development of biological controls for the house dust mite

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the filing of UK patent application GB1513981.9, “Acaricides”, relating to its planned development of biological controls for the house dust mite. The application includes exemplification from the successful feasibility study previously carried out under the direction of Evolution’s Chief Officer, Dr. David Harper.

“This is an important step forward for the company, with claims detailing our initial targets and including important exemplification of the approaches to be taken in this work. It is intended to add additional exemplification during the priority year, building on the current position and developing this promising technology” said Dr. Harper.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts
Email: enquiries@evolutionbiotech.com
Website: www.evolutionbiotech.com